NHL: Diffuse Large B-Cell Lymphoma Pathways

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
<tr>
<td>Pathology:</td>
<td>Stage:</td>
</tr>
<tr>
<td>Line of Therapy:</td>
<td>ECOG Performance Status:</td>
</tr>
<tr>
<td>Biomarkers/Characteristics: (select all that apply)</td>
<td>CD20 status:</td>
</tr>
</tbody>
</table>

**First Line of Therapy (1st Line)**

- **R-CHOP (21)**: cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab*

**First Line of Therapy (1st Line) | Contraindication to Anthracycline**

- **R-CEOP**: cyclophosphamide, etoposide (Toposar), vincristine (Vincasar), prednisone, and rituximab*

**Second and Subsequent Lines of Therapy (2nd Line+) | Transplant Candidates**

- **R-GDP**: gemcitabine (Gemzar), dexamethasone, cisplatin, and rituximab*
- **R-GDP**: gemcitabine (Gemzar), dexamethasone, carboplatin, and rituximab*
- **R-ICE**: ifosfamide (Ifex), carboplatin, etoposide (Toposar), and rituximab*

**Second and Subsequent Lines of Therapy (2nd Line+) | Non-Transplant Candidates**

- **BR**: bendamustine (Bendeka, Treanda) and rituximab*
- **R-GDP**: gemcitabine (Gemzar), dexamethasone, cisplatin, and rituximab*
- **R-GDP**: gemcitabine (Gemzar), dexamethasone, carboplatin, and rituximab*
- **R-GemOx**: gemcitabine (Gemzar), oxaliplatin, and rituximab*

*Rituximab may be administered as Rituxan or Rituxan Hycela. When Rituxan Hycela is chosen, treatment with SC rituximab (Rituxan Hycela) should only be initiated after patients have received at least one full dose of IV rituximab (Rituxan).